For example, CD133+ patient-derived glioblastoma stem cells are able to secrete TGFβ to inhibit NKG2D expression on peripheral blood monocytes, thereby affecting NK cell function (Beier et al., 2012). The gene discussed is KLRK1; the disease is glioblastoma.